- Measure
- What actually changed in the study?
- Comparison
- Was there a suitable control group?
- Outcome
- Did the study measure an effect patients can feel?
On this page
Vitamin infusions, NAD+, hormone treatment, PRP, stem cells and shockwave therapy are sometimes sold under the same longevity label. They were developed or studied for different purposes. An effect on a biological pathway tells us little about whether a person will live longer or remain healthier as they age.
To evaluate healthy aging in men, it is necessary to first determine what the goal is. Improving erection quality, treating hypogonadism, reducing the risk of cardiovascular disease and prolonging life are different outcomes. If a study only shows a change in laboratory measurement, this does not prove the same level of benefit in patient quality of life or health outcomes.
What counts as evidence?
Cell culture and animal studies help understand biological mechanisms. Observational studies investigate relationships in humans. Randomized controlled trials provide more robust data to evaluate the impact of an intervention when designed appropriately. A systematic review is not independent of the quality of the studies it contains. Precision does not automatically increase when low-quality studies are combined.
Especially in the field of longevity, the method by which results such as ‘biological age is decreasing’ is measured should be investigated. Although epigenetic clocks have been used in research, it cannot be concluded that a short-term change in a single measurement reduces the risk of clinical disease or longevity.
NAD+ and vitamin infusions
Nicotinamide adenine dinucleotide (NAD+) is a molecule involved in cellular energy metabolism and many biochemical processes. Cellular studies related to aging have focused attention on NAD metabolism.
Grant et al’s pilot study measured metabolites in blood and urine during a six-hour NAD+ infusion. No conclusions about lifespan, daily function, or sexual health can be drawn from such a measurement.
Preparation conditions for products administered intravenously also pose risks. The US Food and Drug Administration (FDA) stated that it had received reports of tremors, vomiting and fatigue after some prepared NAD+ injections. FDA warns against the use of ingredients that are not suitable for sterile drug preparation.
Stem cell and exosome procedures
Stem cell and extracellular vesicle/exosome research is of interest in terms of tissue repair and signaling mechanisms. Some experimental studies of penile tissue have examined regenerative treatment of erectile dysfunction.
However, results seen in animal models or small and uncontrolled human series are not sufficient for clinical use. Cell type, production method, route of administration, and standardization of the product vary between studies. Long-term safety and efficacy data are limited.
The EAU is evaluating stem cell treatments for erectile dysfunction at an investigational stage. It should not be presented as a proven and risk-free rejuvenation practice instead of standard urological treatments.
PRP and the P-Shot
Platelet-rich plasma (PRP) is a platelet-containing product prepared from a person’s blood and concentrated by different methods. It has been researched in erectile dysfunction and some sexual health symptoms.
Preparation protocols, application numbers, control groups and patient selection differ in studies. Some of the smaller studies reported improvements in erectile function scores. However, it has not been shown that this translates into long-term clinical benefit and is valid for all men.
The use of the commercial designation ‘P-Shot’ also does not change the level of evidence for application. The fact that the material used is obtained from the person’s own blood does not automatically mean that the procedure is risk-free.
Shockwave therapy
Low-intensity shock wave therapy (Li-ESWT) has been evaluated specifically in studies of vascular erectile dysfunction. Some randomised studies have shown improvement on erectile function scales. However, protocols and follow-up periods are heterogeneous.
These results do not mean that the method is the definitive solution for all erection problems. The same response cannot be expected in people with advanced neuropathy due to diabetes, severe vascular disease or significant psychosexual factors.
There may be data on shock wave therapy reducing pain in Peyronie’s disease. However, its use to correct penile curvature is not recommended in the EAU guideline. Chronic pelvic pain, erectile dysfunction and Peyronie’s are different indications. The results are not interchangeable.
Testosterone and other hormones
Testosterone replacement may be used with specific clinical goals in confirmed hypogonadism. There is insufficient evidence to support the use of routine to slow aging in men with normal testosterone levels. It can also suppress sperm production and requires monitoring.
Growth hormone is also not an automatic option for healthy aging practices outside of proven endocrine deficiencies. Various risks may arise, from water retention to changes in glucose metabolism. The phrase ‘hormonal optimization’ should not obscure the actual diagnosis and indication for treatment.
When GLP-1 medicines are used
Drugs such as semaglutide or tirzepatide can be used in the management of obesity and/or diabetes in appropriate indications. Related randomised trials have produced data on weight loss and cardiometabolic outcomes in some patient groups.
However, it cannot be said that these drugs are anti-aging treatments for everyone, definitely improve sperm quality, or directly treat erectile dysfunction. Drug indication, contraindications and safety monitoring should be determined according to the clinical characteristics of the patient.
Keeping everyday function
Smoking cessation, risk-compatible physical activity, control of diabetes and hypertension, recognition of sleep disorders, and shared decision-making for necessary cancer screenings are approaches with better defined clinical benefits.
These practices are not recommended equally for every patient. The person’s age, accompanying diseases and preferences are taken into account. When evaluating supplements, the following questions should be asked: What health outcome will this procedure improve, is there human research to support it, and what are the known risks?
How to read a biological age report
Clocks based on DNA methylation derive an age or risk estimate from patterns in specific samples. If two tests use different methods and reference groups, they may give different results in the same person. In a study, changing the hour value is not enough to show that a person’s risk of disease is reduced or that they will live longer.
It is helpful to ask what decision the outcome would change. Established measurements such as blood pressure, blood sugar, or kidney function have defined uses in clinical decisions. Examining the limits of clinical use of epigenetic clocks, the review discusses the inadequacy of existing data and thresholds to make an individualized treatment decision. (From Population Science to the Clinic? Limits of Epigenetic Clocks as Personal Biomarkers)
Common questions
Does NAD+ infusion rejuvenate men?
It has not been proven to extend lifespan or clinically reverse biological age in humans.
Do exosomes and stem cells treat erectile dysfunction?
There is research in this field. Routine treatment effectiveness and long-term safety have not been adequately validated.
Are PRP and ESWT the same treatment?
No. There are different mechanisms, applications and levels of evidence.
Does testosterone supplements slow down aging?
Its use for this purpose is not supported in men with normal testosterone levels.
In the testosterone deficiency guide, you can find out what findings hormone therapy is on the agenda, and in the shock wave therapy guide, you can find where this method is evaluated in urology.
Related reading
- Low testosterone in men: assessment of hypogonadism
- Shockwave Therapy for Erectile Dysfunction: Who May Benefit?
Experimental treatments should not replace validated treatments.
Sources8 sources
- EAU Guidelines on Erectile Dysfunction
- EAU Guidelines on Male Hypogonadism
- EAU Guidelines on Penile Curvature
- TRAVERSE, cardiovascular safety of testosterone, NEJM 2023
- WHO Guidelines on Physical Activity and Sedentary Behaviour
- From Population Science to the Clinic? Limits of Epigenetic Clocks as Personal Biomarkers
- Grant et al., pilot study of intravenous NAD+, 2019
- FDA communication on ingredients used in sterile compounding